• In late June 2026, ICU Medical, Inc. was removed from several major Russell growth and small‑cap benchmarks, including the Russell 2000 and Russell 3000 Growth indexes, following their latest index reconstitution.
• This broad removal from widely tracked benchmarks matters because it can alter trading flows from index-linked investors and reshape how ICU Medical is positioned in many institutional portfolios.
• Next, we’ll examine how ICU Medical’s removal from several Russell growth indexes may influence its existing investment narrative and risk profile.

Find 45 companies with promising cash flow potential yet trading below their fair value.

ICU Medical Investment Narrative Recap

To own ICU Medical today, you have to believe in steady, long term global demand for infusion therapies and the company’s ability to convert that demand into improving profitability despite tariff, integration, and regulatory pressures. Its removal from several Russell growth indexes mainly affects index related trading rather than the core business, so it does not materially change the near term focus on stabilizing margins and managing product quality and recall risk.

The most relevant recent development is the series of FDA classified recalls affecting Plum infusion pumps and certain Oncology kits, which directly ties into ICU Medical’s key execution and regulatory risks. These recalls could influence how quickly the company benefits from its installed base replacement cycle and innovation pipeline, and they may offset some of the positive impact from recent profitability improvements if remediation and compliance costs remain elevated.

Yet behind the index changes, there is still the question of how much ongoing recall and regulatory risk investors should be aware of...

ICU Medical's narrative projects $2.4 billion revenue and $159.5 million earnings by 2029.

Uncover how ICU Medical's forecasts yield a $172.50 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members currently converge on a single fair value estimate of US$172.50 for ICU Medical, highlighting just one retail viewpoint so far. Set this against the recent product recalls and regulatory scrutiny, and it becomes even more important to compare different risk assessments and explore several alternative perspectives before forming your own view.

Explore another fair value estimate on ICU Medical - why the stock might be worth just $172.50!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your ICU Medical research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free ICU Medical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ICU Medical's overall financial health at a glance.

Looking For Alternative Opportunities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.